Azitra Inc - AZTR STOCK NEWS

Azitra (AZTR) reported Q3 2024 financial results and business updates. Key highlights include completing a $10 million follow-on offering, dosing the first Netherton syndrome patient with ATR-12, and receiving FDA Fast Track designation for ATR-04. Financial results show zero service revenue compared to $310,700 in Q3 2023, R&D expenses of $1.0 million (up from $0.5 million), and G&A expenses of $1.9 million. The company reported a net loss of $1.0 million and held cash and equivalents of $7.3 million as of September 30, 2024. Upcoming milestones include initial safety data and first patient dosing for key trials in Q1 2025.

Azitra (NYSE American: AZTR) announces its participation at BIO-Europe 2024 in Stockholm, Sweden, scheduled for Monday, November 4, 2024, at 2:30pm CET. Travis Whitfill, Chief Operating Officer, will deliver a corporate presentation highlighting the company's pipeline progress, particularly focusing on two key developments: ATR-12 for Netherton syndrome and ATR-04 for EGFR inhibitor-induced dermal toxicity.

The company reports significant achievements in 2024, including the first patient dosing with ATR-12 and receiving FDA Fast Track designation for ATR-04. The presentation will take place at Stockholmsmässan, with opportunities for one-on-one meetings through the BIO One-on-One Partnering system.

Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company specializing in precision dermatology, has been invited to present at the 2024 Maxim Healthcare Virtual Summit. The event, hosted by Maxim Group , will take place from October 15-17, 2024.

Azitra's Chief Operating Officer, Travis Whitfill, will participate in a panel presentation on Thursday, October 17, 2024, at 2:00 p.m. ET. The presentation will be part of the rare disease panel, featuring Azitra alongside other companies such as Quoin Pharmaceuticals, Rezolute, and Zevra Therapeutics.

The summit will showcase a range of biotechnology, diagnostic, medical device, and healthcare information technology companies. Maxim Senior Analysts will host interactive discussions with CEOs and key management, providing insights into various healthcare sectors.

Azitra, Inc. (NYSE American: AZTR) announced a late-breaking presentation at the European Academy of Dermatology and Venereology (EADV) Congress 2024 in Amsterdam. Dr. Mary Spellman will present on September 26, 2024, discussing the development of ATR-04, a live biotherapeutic product for treating epidermal growth factor receptor (EGFR) inhibitor-induced dermal toxicity.

ATR-04 is an engineered Staphylococcus epidermidis strain designed to be safer by deleting an antibiotic resistance gene and controlling growth through auxotrophy. It targets EGFRi-associated skin toxicity, which affects approximately 150,000 patients in the United States. Azitra has an active IND for a Phase 1/2 clinical trial of ATR-04, which has received Fast Track designation from the FDA.

The presentation will cover ATR-04's preclinical development and details of the planned clinical trial. It will be available on Azitra's website after the event.

Azitra (NYSE American: AZTR) has received Fast Track Designation from the FDA for ATR-04, a topical treatment for moderate to severe skin rash caused by Epidermal Growth Factor Receptor inhibitors (EGFRi). This designation recognizes the unmet medical need for treating EGFRi-associated dermal toxicity, which affects approximately 150,000 patients in the US, representing a $1 billion market opportunity.

ATR-04 is a live biotherapeutic product containing an engineered Staphylococcus epidermidis strain. Azitra plans to initiate a Phase 1/2 clinical trial by the end of 2024. The Fast Track status may accelerate ATR-04's development and review process, potentially offering cancer patients a much-needed alternative to current off-label treatments or therapy discontinuation.

Azitra Inc. (NYSE American: AZTR), a precision dermatology company, has announced its participation in the H.C. Wainwright 26th Annual Global Investment Conference from September 9-11, 2024. Travis Whitfill, the company's COO, will present an overview of Azitra at the conference.

Key details:

• The on-demand presentation will be available from September 9, 2024, at 7:00 a.m. ET
• Company management will participate in one-on-one meetings during the event
• The presentation will be held at the Lotte New York Palace Hotel, New York City
• An archived replay will be available on Azitra's website for at least 30 days after the conference

This presentation offers investors an opportunity to gain insights into Azitra's operations and future prospects in the precision dermatology field.

Azitra (NYSE American: AZTR) has initiated dosing in its Phase 1b clinical trial of ATR-12 for Netherton syndrome, a chronic genetic skin disease. The study will enroll about 12 adult patients with twice-daily treatment for 14 days, focusing on safety and tolerability as primary endpoints. Secondary endpoints include efficacy signals and biomarkers. Azitra expects to report interim safety data in early 2025 and full results in the second half of 2025.

ATR-12 is a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of an active LEKTI protein subunit. The multicenter, randomized, double-blind, vehicle-controlled study (NCT06137157) will treat patients with 109 CFU / g of ATR-12 or its vehicle control twice daily on contralateral body sides.

Azitra (NYSE American: AZTR) has received FDA clearance for an IND application to conduct a Phase 1/2 clinical study of ATR-04, targeting moderate to severe EGFR inhibitor-associated dermal toxicity. This condition affects an estimated 150,000 patients in the US, representing a global market size exceeding $1 billion. ATR-04, a live biotherapeutic product, has shown promise in preclinical studies by reducing IL-36γ and Staphylococcus aureus, key factors in EGFRi-associated skin rash. The company plans to initiate a multicenter, randomized, controlled trial by the end of 2024. This development expands Azitra's clinical pipeline, addressing a significant unmet need for cancer patients receiving EGFR inhibitors who often experience severe skin side effects.

Azitra (NYSE American: AZTR) has screened the first patient for its Phase 1b clinical trial of ATR-12, a potential treatment for Netherton syndrome. The trial aims to enroll 12 adult patients for a 14-day treatment period. Interim safety data is expected in early 2025, with full results anticipated in the second half of 2025.

ATR-12 is a proprietary strain of Staphylococcus epidermidis engineered to express therapeutic levels of an active LEKTI protein subunit. The trial's primary endpoints focus on safety and tolerability, while secondary endpoints assess efficacy signals and biomarkers. Recent preclinical data showed ATR-12's potential to reduce IL-36γ by 93% and significantly decrease protease activity in skin samples.